The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research

Journal of Neural Transmission, Supplement

Volumn , Issue 48, 1996, Pages 29-43

  Magyar, K ^a,b,c  

^a Department of Pharmacodynamics ^*  (Hungary)

^b Experimental Cancer Research   (Hungary)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROPROTECTIVE AGENT; OXIDOPAMINE; SELEGILINE; DOPAMINE; NEUROTOXIN; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; CELL CULTURE; CLINICAL ARTICLE; DOPAMINERGIC SYSTEM; HUMAN; MELANOMA CELL; NONHUMAN; PARKINSON DISEASE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; AGE; ANIMAL; CELL STRAIN; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; HYPERTENSION; METABOLISM; RAT;

AGE FACTORS; ANIMALS; APOPTOSIS; DOPAMINE; HUMANS; HYPERTENSION; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NOREPINEPHRINE; PARKINSON DISEASE; PC12 CELLS; RATS; SELEGILINE;

EID: 0030300160     PISSN: 03036995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Ansari KS, Tatton WO, Yu PH, Kruck TPA (1993) Rescue of axotomised immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci 13: 4042-4053
2. Barber AJ, Paterson IA, Gelowitz DL, Voll CL (1993) Deprenyl protects rat hippocampal pyramidal cells from ischaemic insult. Soc Neurosci Abstr 19: P1646
3. Berry MD, Juorio AV, Paterson IA (1994) The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 42: 375-391
4. Bertocci B, Gill G, Da Prada M (1988) Prevention of the DSP-4-induced noradrenergic neurotoxicity by irreversible, not by reversible MAO-B inhibitors. Pharmacol Res Commun 20: 131-132
5. Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti-akinetic effect of L-dopa treatment by an inhibitor of MAO-B, 1-deprenyl. J Neural Transm 36: 303-336
6. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Martin J (1985) Increased life expectancy resulting from addition of 1-deprenyl to Madopar® treatment in Parkinson's disease: a long-term study. J Neural Transm 64:113-128
7. Brodie BB, Cho AK, Gessa GL (1970) Possible role of p-hydroxynorephedrine in the depletion of norepinephrine induced by d-amphetamine and in tolerance to this drug. In: Costa E, Garattini S (eds) Amphetamines and related compounds. Raven Press, New York, pp 217-230
8. Carrillo MC, Kanai S, Nokubo M, Kitani K (1991) (-)-Deprenyl induces activities of both Superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci 48: 517-521
9. Clow A, Hussain T, Glover V, Sandier M, Dexter DT, Walker M (1991) (-)-deprenyl can induce soluble Superoxide dismutase in rat striata. J Neural Transm 86: 77-80
10. Da Prada M (1991) New approaches to the treatment of age-related brain disorders. Can J Neurol Sci 18: 384-386
11. Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE (1984) The pharmacology of Parkinson's disease: basic aspects and recent advances. Experiencia 40: 1165-1172
12. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Marti JS (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl] 29: 279-292